膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光法)
Multiplex Assay Kit for Annexin A2 (ANXA2) ,etc. by CBA (Cytometric Bead Array)
ANX-A2; ANX2L4; CAL1H; LIP2; LPC2; LPC2D; P36; PAP-IV; Protein I; Chromobindin-8; Calpactin-1 heavy chain; Lipocortin II; Placental anticoagulant protein IV
- 編號CMB944Hu
- 物種Homo sapiens (Human,人)相同的名稱,不同的物種。
- 實驗方法雙抗夾心
- 反應時長4h
- 檢測范圍0.0098-10ng/mL
- 靈敏度最小可檢測劑量小于等于0.0033ng/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載英文說明書 中文說明書
- 規(guī)格48T96T
- 價格¥ 3352¥ 4788
- 欲了解實際交易價格和更多情況,請與當?shù)亟涗N商聯(lián)系!
特異性
本試劑盒用于檢測膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光法),經檢測與其它相似物質無明顯交叉反應。
由于受到技術及樣本來源的限制,不可能完成對所有相關或相似物質交叉反應檢測,因此本試劑盒有可能與未經檢測的其它物質有交叉反應。
回收率
分別于定值血清及血漿樣本中加入一定量的膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光法)(加標樣品),重復測定并計算其均值,回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 87-97 | 93 |
| EDTA plasma(n=5) | 80-92 | 87 |
| heparin plasma(n=5) | 95-102 | 99 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內差:取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續(xù)測定20 次,分別計算不同濃度樣本的平均值及SD值。
批間差:選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定,每個樣本使用同一試劑盒重復測定8次,分別計算不同濃度樣本的平均值及SD值。
批內差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內加入適量的膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測樣本,線性范圍即為稀釋后樣本中膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 92-101% | 87-95% | 91-101% | 89-105% |
| EDTA plasma(n=5) | 84-93% | 82-96% | 82-101% | 79-104% |
| heparin plasma(n=5) | 80-99% | 78-92% | 89-99% | 87-96% |
穩(wěn)定性
經測定,試劑盒在有效期內按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響,實驗室的環(huán)境條件需盡量保持一致,尤其是實驗室內溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1、向實驗板每孔內加入200μL分析緩沖液以預濕;
2、實驗前標準品、試劑及樣本準備;
3、加樣(標準品、樣本、磁珠),標準品或樣本100μL及磁珠10μL,25°C酶標板振蕩器孵育2小時;
4、磁吸甩干,加檢測溶液A 100μL,25°C酶標板振蕩器孵育1小時;
5、磁吸甩干,加檢測溶液B 100μL,25°C振動孵育30分鐘;
6、磁吸洗板1次;
7、加鞘液100μL,旋渦震蕩10分鐘后讀數(shù)。
實驗原理
將膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光法)抗體包被于磁性微球表面,制成固相載體,向微孔中分別加入標準品或標本以及磁珠,其中的膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光法)與連接于固相載體上的抗體結合,然后加入生物素化的膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光法)抗體,加入PE標記的親和素,用流式細胞儀讀數(shù)。MFI值和樣品中的膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光法)濃度呈正相關。
贈品
增值服務
相關產品
| 編號 | 適用物種:Homo sapiens (Human,人) | 應用(僅供研究使用,不用于臨床診斷!) |
| RPB944Hu03 | 膜聯(lián)蛋白A2(ANXA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPB944Hu01 | 膜聯(lián)蛋白A2(ANXA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPB944Hu04 | 膜聯(lián)蛋白A2(ANXA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APB944Hu01 | 膜聯(lián)蛋白A2(ANXA2)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPB944Hu02 | 膜聯(lián)蛋白A2(ANXA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB944Hu01 | 膜聯(lián)蛋白A2(ANXA2)多克隆抗體 | WB,IHC |
| PAB944Hu02 | 膜聯(lián)蛋白A2(ANXA2)多克隆抗體 | WB; IHC; FCM |
| LAB944Hu71 | 膜聯(lián)蛋白A2(ANXA2)多克隆抗體(生物素標記) | IHC |
| MAB944Hu22 | 膜聯(lián)蛋白A2(ANXA2)單克隆抗體 | IHC |
| MAB944Hu21 | 膜聯(lián)蛋白A2(ANXA2)單克隆抗體 | WB; FCM |
| FAB944Hu08 | 抗膜聯(lián)蛋白A2(ANXA2)單克隆抗體 | FCM |
| FAB944Hu06 | 抗膜聯(lián)蛋白A2(ANXA2)單克隆抗體 | FCM |
| FAB944Hu04 | 抗膜聯(lián)蛋白A2(ANXA2)單克隆抗體 | FCM |
| FAB944Hu02 | 抗膜聯(lián)蛋白A2(ANXA2)單克隆抗體 | FCM |
| SEB944Hu | 膜聯(lián)蛋白A2(ANXA2)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCB944Hu | 膜聯(lián)蛋白A2(ANXA2)檢測試劑盒(化學發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| CMB944Hu | 膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光法) | FLIA Kit for Antigen Detection. |
| LMB944Hu | 膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Journal of Cellular Biochemistry | Subcellular proteome analysis unraveled annexin A2 related to immune liver fibrosis[PubMed: 20225235] |
| World Journal of Gastroenterology | Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma[PubMed: PMC3491596] |
| Oncology Letters | Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis[PubMed: PMC3742823] |
| Ibrahim | Annexin A2 Versus Afp as An Efficient Diagnostic Serum Marker for Hepatocellular Carcinoma[Ghrnet: Source] |
| European Journal of Clinical Microbiology & Infectious Diseases | Serum annexin A2 levels in acute brucellosis and brucellar spondylodiscitis[Pubmed:24853056] |
| Biomedicine & Pharmacotherapy | Circulating annexin A2 as a biomarker in gastric cancer patients: Correlation with clinical variables[Pubmed:25661364] |
| Hepat Mon | Serum Levels of Annexin A2 as a Candidate Biomarker for Hepatic Fibrosis in Patients With Chronic Hepatitis B[PubMed: 26587036] |
| Tumour Biol | Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma[PubMed: 26109000] |
| Biomed Pharmacother | Circulating[PubMed: 25661364] |
| Tumour Biol | Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma[PubMed: 26189841] |
| Eur J Clin Invest | Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population[PubMed: 26081791] |
| Journal of Oral and Maxillofacial Surgery | Serum?Annexin?A2?Level?Is?Associated?With?Diagnosis?and?Prognosis?in?Patients?With?OralSquamous?Cell?Carcinoma.[pubmed:27889534] |
| Pregnancy Hypertens | Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: A pilot study.[pubmed:28501283] |
| Mol Nutr Food Res. | Epigallocatechin gallate induces an up-regulation of LDL receptor accompanied by a reduction of PCSK9 via the annexin A2-independent pathway in HepG2 cells.[pubmed:28181408] |
| Archives of Gynecology and Obstetrics | Expression of annexin A2 in adenomyosis and dysmenorrhea[Pubmed: 31183557] |
| Cancers | Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer[Pubmed: 31842290] |
| PLASMA BIOMARKER FOR OVARIAN CANCER[] | |
| Diagnostics | Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer. Diagnostics 2021, 11, 69[33406648] |
| ADVANCED RESEARCHES | Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C[] |
| Cancer Cell International | Bufalin Induced Mitochondrial Dysfunction Promotes Apoptosis of Glioma Cells by Regulating Annexin A2 and DRP1 Proteins[] |
| Cancer Cell Int | Bufalin induces mitochondrial dysfunction and promotes apoptosis of glioma cells by regulating Annexin A2 and DRP1 protein expression[34376212] |


